pmprb

1:48PM
Printer-friendly version
Pandemic showed that Canada needs a thriving biopharmaceutical industry

Government policies and regulations have created an environment hostile to research and innovation.


12:02PM
Printer-friendly version
Proposed ‘drug price’ changes threaten access for Canadian patients

Advanced clinical trials in Canada, which were consistent between 2015 and 2019, decreased by 26 per cent in 2020.


10:38AM
Printer-friendly version
Approving new drugs in Canada—a 30-year review

Regardless of their potential impact on patient health, drug approval times in Canada were longer than in other countries.


1:05PM
Printer-friendly version
Canada should permanently expand drug approval process in post-COVID world

Accepting FDA approvals could lead to earlier marketing availability in Canada.


9:54AM
Printer-friendly version
Ottawa postpones short-sighted drug-pricing regulations

Planned changes would likely result in fewer new and innovative drugs available to Canadians.


7:40PM
Printer-friendly version
Ottawa’s changes to drug-pricing will deny some Canadians potentially lifesaving drugs

Forcing manufacturers of high-cost drugs to reduce their prices by up to 80 per cent is unsustainable.